CFO departure
Celldex Therapeutics, Inc. discloses CFO departure: Sam Martin
Celldex Therapeutics, Inc. reported in a Form 8-K filed July 15, 2026 a change involving its Chief Financial Officer, Sam Martin, effective March 31, 2027. The filing's own words are quoted below.
In the filing's words
On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Celldex Therapeutics, Inc. (CLDX) |
|---|---|
| Event | Departure |
| Outgoing | Sam Martin |
| Effective | March 31, 2027 |
| 8-K filed | July 15, 2026 |
| SEC CIK | 0000744218 |
Celldex Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed July 15, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Sam Martin? Send a correction with the primary source.